According to a new report Global Uveitis Treatment Market, published by KBV research, The Global Uveitis Treatment Market size is expected to reach $686.1 Million by 2025, rising at a market growth of 5.5% CAGR during the forecast period.

Due to the higher prevalence of uveitis, the anterior uveitis segment is projected to depict substantial growth during the forecast period. Anterior uveitis is the most common type of uveitis described by an inflammation of the eye's middle layer, it involves the iris and adjacent tissue, known as the ciliary. The Posterior Uveitis market is expected to witness a CAGR of 6% during (2019 - 2025).

Anti-inflammatory is currently a major segment contributing to sales and is expected to rise dramatically over the projected period due to the use of anti-inflammatory treatment as a first-line uveitis treatment. The Immunotherapy & Targeted Therapies market is witnessing a CAGR of 5.8% during (2019 - 2025).
With the sudden break of Covid-19 in late months of year 2019, the markets worldwide are unfortunately experiencing its grip. The suppliers and consumers of the products & Services are affected in a big way across the sectors resulting in declining revenues in last quarters of year 2019.

The North America market dominated the Global Uveitis Treatment Market by Region in 2018. Asia-Pacific offers lucrative opportunities for key players operating on the market for uveitis treatment due to increased awareness of uveitis therapy and increased use of uveitis care products. In addition, improving the healthcare infrastructure, growing the number of target populations, expanding the R&D industry, growing healthcare reforms, and advancing healthcare technology further contribute to market growth. The Europe market is poised to grow at a CAGR of 5% during (2019 - 2025).

Structural Insights: https://www.kbvresearch.com/uveitis-treatment-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of AbbVie, Inc., Alimera Sciences, Inc., Enzo Biochem, Inc., Amgen, Inc., Bausch Health Companies, Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., TopiVert Ltd., and Novartis AG.

Global Uveitis Treatment Market Segmentation

By Drug Class
• Anti-inflammatory
• Immunotherapy & Targeted Therapies
• Antimicrobial Drugs
• Other Drug Class

By Disease Type
• Anterior Uveitis
• Posterior Uveitis
• Intermediate Uveitis
• Panuveitis

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online stores

By Geography

North America
• US
• Canada
• Mexico
• Rest of North America

Europe
• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

LAMEA
• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Companies Profiled
• AbbVie, Inc.
• Alimera Sciences, Inc.
• Enzo Biochem, Inc.
• Amgen, Inc.
• Bausch Health Companies, Inc.
• Clearside Biomedical, Inc.
• EyePoint Pharmaceuticals, Inc.
• Santen Pharmaceutical Co., Ltd.
• TopiVert Ltd.
• Novartis AG